HIV and Cancer Remission: The Story of the Patient of Oslo
- A 63-year-old man in Chad has achieved sustained remission from both HIV and an aggressive blood cancer following a stem cell transplant, marking one of the few documented...
- The patient, whose identity has not been disclosed, was diagnosed with HIV in 2010 and later developed acute myeloid leukemia (AML) in 2022.
- Following the transplant, the patient stopped antiretroviral therapy (ART) under close medical supervision as part of a research protocol aimed at testing whether the new immune system could...
A 63-year-old man in Chad has achieved sustained remission from both HIV and an aggressive blood cancer following a stem cell transplant, marking one of the few documented cases worldwide where dual eradication of these life-threatening conditions has been reported.
The patient, whose identity has not been disclosed, was diagnosed with HIV in 2010 and later developed acute myeloid leukemia (AML) in 2022. After failing to respond to standard chemotherapy, he underwent a haploidentical stem cell transplant in early 2023 using cells from a half-matched donor — a procedure typically reserved for high-risk blood cancers when fully matched donors are unavailable.
Following the transplant, the patient stopped antiretroviral therapy (ART) under close medical supervision as part of a research protocol aimed at testing whether the new immune system could control HIV without medication. More than 18 months after discontinuing ART, repeated ultrasensitive tests have failed to detect HIV RNA or DNA in his blood, tissues, or cerebrospinal fluid. Simultaneously, he has remained in complete remission from AML with no signs of relapse.
How the transplant led to dual remission
The success appears linked to the unique biological properties of the donor’s stem cells. Genetic testing revealed that the donor carried a homozygous mutation in the CCR5 gene — known as CCR5Δ32 — which confers natural resistance to HIV by preventing the virus from entering CD4+ T cells. This same mutation was famously present in the stem cell donors of the Berlin, London, and Düsseldorf patients, the only other individuals confirmed to have been cured of HIV through transplantation.
In this case, however, the transplant was not from a fully matched unrelated donor but from a haploidentical relative — meaning the donor shared only half of the patient’s human leukocyte antigen (HLA) markers. This approach increases the risk of graft-versus-host disease (GVHD) and complications, yet the patient experienced only mild, manageable GVHD and did not require prolonged immunosuppression.
Context: HIV cure research and stem cell transplantation
To date, only seven people worldwide are considered to have been cured of HIV, all following stem cell transplants for underlying blood cancers. The first, Timothy Ray Brown (the “Berlin patient”), was treated in 2007 and remained HIV-free until his death in 2020. Subsequent cases have refined the approach, demonstrating that CCR5-deficient stem cells can reconstitute an immune system resistant to HIV infection when combined with the elimination of the viral reservoir through conditioning regimens like chemotherapy and radiation.
However, stem cell transplantation remains a high-risk procedure, carrying a mortality rate of 5–20% even in specialized centers. It is not considered a viable cure strategy for the millions of people living with HIV who do not have life-threatening hematologic malignancies requiring such intervention. Instead, these cases serve as proof-of-concept studies, informing gene therapy strategies aimed at replicating the CCR5 mutation in a patient’s own stem cells.
Ongoing monitoring and scientific scrutiny
The Chad case is being monitored by an international collaboration of researchers from the Institut Pasteur in Paris, the National Institutes of Health (NIH), and local health authorities in N’Djamena. Blood and tissue samples are being analyzed using ultrasensitive assays capable of detecting fewer than one copy of HIV per million cells — the current gold standard for confirming remission.
To rule out residual virus, investigators have also performed HIV outgrowth assays, which attempt to reactivate any latent virus in resting CD4+ T cells, and examined lymphoid tissue biopsies. To date, no replication-competent virus has been found. Researchers emphasize, however, that long-term follow-up — ideally five years or more post-treatment — is required before declaring a definitive cure, as rare late viral rebounds have occurred in other remission cases.
Dr. Françoise Barré-Sinoussi, Nobel laureate and co-discoverer of HIV, commented in a recent interview with Institut Pasteur publications that while such cases remain exceptional, they provide critical insights into where and how HIV persists in the body. “Each cured patient teaches us something new about the viral reservoir and the immune mechanisms that can ultimately eliminate it,” she said.
Implications and future directions
The case underscores the potential of CCR5-targeted approaches, whether through transplantation, gene editing, or therapeutic vaccines, to achieve HIV remission. Ongoing clinical trials are testing CRISPR-based gene editing to disrupt the CCR5 gene in autologous stem cells, with early results showing safety and proof of concept, though efficacy and scalability remain under investigation.
For now, antiretroviral therapy remains the standard of care for HIV, enabling people with the virus to live long, healthy lives when taken consistently. Experts stress that no one should stop ART outside of a closely monitored clinical trial, as doing so can lead to rapid viral rebound and deterioration of immune function.
As research continues, each documented case of HIV remission — especially those involving innovative transplant strategies like haploidentical donation — adds valuable data to the pursuit of a scalable, safe, and widely accessible cure.